Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Clover Health Investments Corp (NASDAQ: CLOV) closed at $2.61 in the last session, down -1.51% from day before closing price of $2.65. In other words, the price has decreased by -$1.51 from its previous closing price. On the day, 5.64 million shares were traded. CLOV stock price reached its highest trading level at $2.71 during the session, while it also had its lowest trading level at $2.61.
Ratios:
We take a closer look at CLOV’s different ratios to gain a better understanding of the stock. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on December 17, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On October 07, 2024, UBS started tracking the stock assigning a Neutral rating and target price of $4.
Cowen Upgraded its Underperform to Market Perform on February 02, 2022, whereas the target price for the stock was revised from $7 to $3.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 13 ’25 when Loengard Anna U bought 26,500 shares for $2.59 per share. The transaction valued at 68,755 led to the insider holds 29,610 shares of the business.
Garipalli Vivek bought 415,000 shares of CLOV for $929,600 on Aug 07 ’25. The Director now owns 1,824,267 shares after completing the transaction at $2.24 per share. On Aug 08 ’25, another insider, Garipalli Vivek, who serves as the Director of the company, bought 31,980 shares for $2.17 each. As a result, the insider paid 69,397 and bolstered with 1,856,247 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 1337658880 and an Enterprise Value of 1136385792. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.83 while its Price-to-Book (P/B) ratio in mrq is 3.66. Its current Enterprise Value per Revenue stands at 0.707 whereas that against EBITDA is -27.676.
Stock Price History:
The Beta on a monthly basis for CLOV is 1.97, which has changed by -0.15806454 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, CLOV has reached a high of $4.87, while it has fallen to a 52-week low of $2.12. The 50-Day Moving Average of the stock is -8.32%, while the 200-Day Moving Average is calculated to be -24.52%.
Shares Statistics:
According to the various share statistics, CLOV traded on average about 9.34M shares per day over the past 3-months and 11472400 shares per day over the past 10 days. A total of 390.25M shares are outstanding, with a floating share count of 385.34M. Insiders hold about 24.81% of the company’s shares, while institutions hold 28.66% stake in the company. Shares short for CLOV as of 1753920000 were 41040883 with a Short Ratio of 4.40, compared to 1751241600 on 42080972. Therefore, it implies a Short% of Shares Outstanding of 41040883 and a Short% of Float of 10.08.
Earnings Estimates
The stock of Clover Health Investments Corp (CLOV) is currently being evaluated by 1.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $0.0, with high estimates of $0.0 and low estimates of $0.0.
Analysts are recommending an EPS of between $0.1 and $0.1 for the fiscal current year, implying an average EPS of $0.1. EPS for the following year is $0.19, with 1.0 analysts recommending between $0.19 and $0.19.
Revenue Estimates
According to 4 analysts, the current quarter’s revenue is expected to be $467.18M. It ranges from a high estimate of $475.4M to a low estimate of $455.43M. As of the current estimate, Clover Health Investments Corp’s year-ago sales were $330.99MFor the next quarter, 4 analysts are estimating revenue of $472.87M. There is a high estimate of $486.6M for the next quarter, whereas the lowest estimate is $460.75M.
A total of 4 analysts have provided revenue estimates for CLOV’s current fiscal year. The highest revenue estimate was $1.9B, while the lowest revenue estimate was $1.86B, resulting in an average revenue estimate of $1.88B. In the same quarter a year ago, actual revenue was $1.37BBased on 4 analysts’ estimates, the company’s revenue will be $2.39B in the next fiscal year. The high estimate is $2.6B and the low estimate is $2.25B.
